NCT07012213View on ClinicalTrials.gov

Nasal Dexmedetomidine Versus Systemic Infusion Dexmedetomidine in Reducing Intraoperative Opioid Consumption in Nasal Endoscopic Surgeries

EARLY_PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

October 15, 2025

Primary Completion Date

November 15, 2025

Study Completion Date

December 30, 2025

Conditions
Functional Endoscopic Sinus Surgery (FESS)
Interventions
DRUG

Patients in group A received .5 g/kg/h dexmedetomidine infusion after general anesthesia, in group B received 1 ml (100 mic) dexmedetomidine intranasal spray before induction.

Patients in group A received .5 g/kg/h dexmedetomidine infusion after general anesthesia, in group B received 1 ml (100 mic) dexmedetomidine intranasal spray before induction.

Trial Locations (1)

12913

Kasralaini medical school, Cairo

All Listed Sponsors
lead

Cairo University

OTHER